In a textbook example of an improper subgroup analysis (1) (one defined by events subsequent to randomization, in this case fabricating new "CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events]-like" inclusion criteria), Bhatt et al. (2) present data suggesting that persons with a prior history of stroke, myocardial infarction (MI), or peripheral vascular disease (PVD) may benefit from long-term dual antiplatelet therapy with aspirin plus clopidogrel versus aspirin alone. It is illuminating to examine this analysis in the historical and statistical context of the clinical trial evidence from which it was derived.
In the CAPRIE trial (3), a trial twice as large as this "CAPRIElike" CHARISMA (Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance) subgroup, a marginally statistically significant result (p ϭ 0.043) was observed for the primary end point, with statistical heterogeneity of treatment effect (p ϭ 0.042) being observed between the 3 predefined subgroups of patients with recent stroke, MI, or PVD. Only the PVD subgroup benefited from the use of clopidogrel versus aspirin. Despite statistically stronger evidence of heterogeneity of (p ϭ 0.042) than of overall treatment effect (p ϭ 0.043), the CAPRIE trial's authors concluded that their hypothesis of universal superiority of clopidogrel over aspirin for all vascular disease was correct anyway and presented in their primary manuscript another improper post hoc subgroup analysis designed to make their data comply with their hypothesis. Specifically, they analyzed patients with newly fabricated inclusion criteria of any prior history of coronary artery disease and, unlike the actual CAPRIE trial MI patient subgroup, showed a statistically significant reduction in recurrent vascular events.
History has now repeated itself. The most statistically significant results presented in the primary CHARISMA trial report (4) were excessive "moderate" bleeding events in the dual-therapy group (p Ͻ 0.001) and excess cardiovascular mortality in the predefined primary prevention subcohort (p ϭ 0.01) treated with dual therapy. The primary end point was negative. Ironically, and perhaps predictably, 10 years after the CAPRIE trial, the CHARISMA trial's authors have suddenly selectively embraced the value of heterogeneity of treatment effect (between the primary and secondary prevention subcohorts) statistically evident in the CHARISMA trial (p ϭ 0.045), using it as a philosophical springboard to manipulate the data of the CHARISMA trial to fit their hypothesis of the universal superiority of clopidogrel (this time when combined with aspirin) over aspirin via the currently published analysis. If a randomized trial of aspirin plus clopidogrel versus aspirin alone in a population of patients with any prior history of stroke, MI, and/or PVD is performed, I predict it will show no statistically significant net benefit. 
